YY1 Over-Expression in Human Brain Gliomas and Meningiomas Correlates with TGF-β1, IGF-1 and FGF-2 mRNA Levels

REFERENCES

• Bondy M., Ligon B. L. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol 1996; 29: 197–205
   PubMed Web of Science ®Google Scholar
• Kleihues P., Cavenee W. K. Pathology and Genetics of Tumors of the Nervous System. IARC Press, Lyon 2000; 9–54
   Google Scholar
• Takahashi J. A., Suzui H., Yasuda Y., Ito N., Ohta M., Jaye M., Fukumoto M., Oda Y., Kikuchi H., Hatanaka M. Gene expression of fibroblast growth factor receptors in the tissues of human gliomas and meningiomas. Biochem Biophys Res Commun 1991; 177: 1–7
   PubMed Web of Science ®Google Scholar
• Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988; 62: 2152–2165
   PubMed Web of Science ®Google Scholar
• Kon H., Sonoda Y., Kumabe T., Yoshimoto T., Sekiya T., Murakami Y. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene 1998; 16: 257–263
   PubMed Web of Science ®Google Scholar
• Nozaki M., Tada M., Kobayashi H., Zhang C. L., Sawamura Y., Abe H., Ishii N., Van Meir E. G. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncol 1999; 1: 124–137
   PubMedGoogle Scholar
• Platten M., Wick W., Weller M. M. Malignant glioma biology: Role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001; 52: 401–410
   PubMed Web of Science ®Google Scholar
• Harada T., Irving R. M., Xuereb J. H., Barton D. E., Hardy D. G., Moffat D. A., Maher E. R. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J. Neurosurg. 1996; 84: 847–851
   PubMed Web of Science ®Google Scholar
• Leone P. E., Bello M. J., de Campos J. M., Vaquero J., Sarasa J. L., Pestana A., Rey J. A. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999; 18: 2231–2239
   PubMed Web of Science ®Google Scholar
• Leone P. E., Mendiola M., Alonso J., Paz-y-Mino C., Pestana A. Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker. BMC Cancer 2003; 3: 6
   PubMedGoogle Scholar
• Tucker R. F., Shipley G. D., Moses H. L., Holley R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 1984; 226: 705–707
   PubMed Web of Science ®Google Scholar
• Paulus W., Tonn J. C. Basement membrane invasion of glioma cells mediated by integrin receptors. J Neurosurg 1994; 80: 515–519
   PubMed Web of Science ®Google Scholar
• Yamada N., Kato M., Yamashita H., Nister M., Miyazono K., Heldin C. H., Funa K. Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 1995; 62: 386–392
   PubMed Web of Science ®Google Scholar
• Stiles J. D., Ostrow P. T., Balos L. L., Greenberg S. J., Plunkett R., Grand W., Heffner R. R., Jr. Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol 1997; 56: 435–439
   PubMed Web of Science ®Google Scholar
• Platten M., Wick W., Wild-Bode C., Aulwurm S., Dichgans J., Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun 2000; 268: 607–611
   PubMed Web of Science ®Google Scholar
• Gold L. I., Saxena B., Zagzag B., Miller D. C., Koslow M., Brandeis L., Farmer J. P. Increased expression of TGF-beta isoforms by malignant gliomas. J Cell Biochem 1992; 16B: 123
   Google Scholar
• Takiuchi H., Tada T., Li X. F., Ogata M., Ikeda T., Fujimoto S., Fujiwara H., Hamaoka T. Particular types of tumor cells have the capacity to convert transforming growth factor beta from a latent to an active form. Cancer Res 1992; 52: 5641–5646
   PubMed Web of Science ®Google Scholar
• Weller M., Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995; 21: 128–151
   PubMed Web of Science ®Google Scholar
• Johnson M. D., Okediji E., Woodard A. Transforming growth factor-beta effects on meningioma cell proliferation and signal transduction pathways. J Neurooncol 2004; 66: 9–16
   PubMed Web of Science ®Google Scholar
• Zhang Y., Feng X., We R., Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-beta response. Nature 1996; 383: 168–172
   PubMed Web of Science ®Google Scholar
• Ueba T., Takahashi J. A., Fukumoto M., Ohta M., Ito N., Oda Y., Kikuchi H., Hatanaka M. Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 1994; 34: 221–225, discussion 225–226
   PubMed Web of Science ®Google Scholar
• Och W., Mariak Z., Smolka M., Badowski J., Koziorowski M. Epidermal growth factor expression in brain neoplasms. Neurol Neurochir Pol 2000; 34: 1165–1172
   PubMedGoogle Scholar
• Camby I., Nagy N., Rombaut K., Gras T., Duponchelle C., Pasteels J. L., Brotchi J., Kiss R., Salmon I. Influence of epidermal growth factor and gastrin on the cell proliferation of human meningiomas versus astrocytic tumors maintained as ex vivo tissue cultures. Neuropeptides 1997; 31: 217–225
   PubMed Web of Science ®Google Scholar
• Lund-Johansen M., Forsberg K., Bjerkvig R., Laerum O. D. Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture. Acta Neuropathol (Berl) 1992; 84: 190–197
   PubMed Web of Science ®Google Scholar
• Engebraaten O., Bjerkvig R., Pedersen P. H., Laerum O. D. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumour biopsies in vitro. Int J Cancer 1993; 53: 209–214
   PubMed Web of Science ®Google Scholar
• Pedersen P. H., Ness G. O., Engebraaten O., Bjerkvig R., Lillehaug J. R., Laerum O. D. Heterogeneous response to the growth factors [EGF, PDGF (bb), TGF-alpha, bFGF, IL-2] on glioma spheroid growth, migration and invasion. Int J Cancer 1994; 56: 255–261
   PubMed Web of Science ®Google Scholar
• Antoniades H. N., Galanopoulos T., Neville-Golden J., Maxwell M. Expression of insulin-like growth factors I and II and their receptor mRNAs in primary human astrocytomas and meningiomas; in vivo studies using in situ hybridization and immunocytochemistry. Int J Cancer 1992; 50: 215–222
   PubMed Web of Science ®Google Scholar
• Friend K. E., Radinsky R., McCutcheon I. E. Growth hormone receptor expression and function in meningiomas: Effect of a specific receptor antagonist. J Neurosurg 1999; 91: 93–99
   PubMed Web of Science ®Google Scholar
• Gordon S., Akopyan G., Garban H., Bonavida B. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125–1142
   PubMed Web of Science ®Google Scholar
• Seligson D., Horvath S., Huerta-Yepez S., Hanna S., Garban H., Roberts A., Shi T., Liu X., Chia D., Goodglick L., Bonavida B. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Onco 2005; 27: 131–141
   PubMed Web of Science ®Google Scholar
• Flanagan J. R. Autologous stimulation of YY1 transcription factor expression: Role of an insulin-like growth factor. Cell Growth Differ 1995; 6: 185–190
   PubMedGoogle Scholar
• Santiago F. S., Lowe H. C., Bobryshev Y. V., Khachigian L. M. Induction of the transcriptional repressor Yin Yang-1 by vascular cell injury. Autocrine/paracrine role of endogenous fibroblast growth factor-2. J Biol Chem 2001; 276: 41143–41149
   PubMed Web of Science ®Google Scholar
• Rossner S., Sastre M., Bourne K., Lichtenthaler S. F. Transcriptional and translational regulation of BACE1 expression—Implications for Alzheimer's disease. Prog Neurobiol 2006; 79: 95–111
   PubMed Web of Science ®Google Scholar
• Soufla G., Sifakis S., Baritaki S., Zafiropoulos A., Koumantakis E., Spandidos D. A. VEGF, FGF-2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005; 221: 105–118
   PubMed Web of Science ®Google Scholar
• Soulitzis N., Karyotis I., Delakas D., Spandidos D. A. Expression analysis of peptide growth factors VEGF, FGF-2, TGFB1, EGF and IGF-1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006; 29: 305–314
   PubMed Web of Science ®Google Scholar
• Zhou Y. H., Tan F., Hess K. R., Yung W. K. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res 2003; 9: 3369–3375
   PubMed Web of Science ®Google Scholar
• Jennings M. T., Maciunas R. J., Carver R., Bascom C. C., Juneau P., Misulis K., Moses H. L. TGF beta 1 and TGF beta 2 are potential growth regulators for low-grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis. Int J Cancer 1991; 49: 129–139
   PubMed Web of Science ®Google Scholar
• Bristow R. E., Baldwin R. L., Yamada S. D., Korc M., Karlan B. Y. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 1999; 85: 658–668
   PubMed Web of Science ®Google Scholar
• Matsushita M., Matsuzaki K., Date M., Watanabe T., Shibano K., Nakagawa T., Yanagitani S., Amoh Y., Takemoto H., Ogata N., Yamamoto C., Kubota Y., Seki T., Inokuchi H., Nishizawa M., Takada H., Sawamura T., Okamura A., Inoue K. Down-regulation of TGF-beta receptors in human colorectal cancer: Implications for cancer development. Br JCancer 1999; 80: 194–205
   PubMed Web of Science ®Google Scholar
• Baritaki S., Sifakis S., Huerta-Yepez S., Neonakis I., Soufla G., Bonavida B., Spandidos D. A. Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: Implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 2007; 31: 69–79
   PubMed Web of Science ®Google Scholar
• Fan D., Chakrabarty S., Seid C., Bell C. W., Schackert H., Morikawa K., Fidler I. J. Clonal stimulation or inhibition of human colon carcinomas and human renal carcinomas mediated by transforming growth factor-beta 1. Cancer Commun 1989; 1: 117–125
   PubMedGoogle Scholar
• Manning A. M., Williams A. C., Game S. M., Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): Conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 1991; 6: 1471–1476
   PubMed Web of Science ®Google Scholar
• Silverman E. S., Palmer L. J., Subramaniam V., Hallock A., Mathew S., Vallone J., Faffe D. S., Shikanai T., Raby B. A., Weiss S. T., Shore S. A. Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. Am. J Respir Crit Care Med 2004; 169: 214–219
   PubMed Web of Science ®Google Scholar
• Hobbs K., Negri J., Klinnert M., Rosenwasser L. J., Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am J Respir Crit Care Med 1998; 158: 1958–1962
   PubMed Web of Science ®Google Scholar
• Grainger D. J., Heathcote K., Chiano M., Snieder H., Kemp P. R., Metcalfe J. C., Carter N. D., Spector T. D. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93–97
   PubMed Web of Science ®Google Scholar
• Puduvalli V. K., Li J. T., Chen L., McCutcheon I. E. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 2005; 65: 1547–1553
   PubMed Web of Science ®Google Scholar
• Baritaki S., Huerta-Yepez S., Sakai T., Spandidos D. A., Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: Up-regulation of DR5 and inhibition of YY1. Mol. Cancer Ther 2007; 6: 1387–99
   PubMed Web of Science ®Google Scholar